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Abstract
Background: The objective of this clinical study is to evaluate the safety and effectiveness of the Activ-L Artificial
Disc for treatment of single-level degenerative disc disease of the lumbar spine in patients who have been
unresponsive to at least six months of prior conservative care. The hypothesis of the study is that the Activ-L Disc
is non-inferior to the control (the Charité® Artificial Disc [DePuy Spine] or ProDisc-L® Total Disc Replacement
[Synthes Spine]) with respect to the rate of individual subject success at 24 months. Individual subject success is a
composite of effectiveness and safety.
Methods/Design: The study proposed is a prospective, randomized, single-masked, controlled, multi-center clinical
trial consisting of an estimated 414 subjects with single-level DDD of the lumbar spine (L4/L5, or L5/S1) who have
failed to improve with conservative treatment for at least six months prior to enrollment. After enrollment, subjects
will be randomized in a 2:1 ratio to either the Activ-L Disc (investigational device) or the control (Charité or
ProDisc-L). Radiographic endpoints will be evaluated by an independent reviewer at an imaging core laboratory.
Each subject will be followed for 5 years post-treatment.
Discussion: The safety and effectiveness of the Activ-L Artificial Disc for treatment of single-level degenerative disc
disease of the lumbar spine will be equivalent to Charité® Artificial Disc [DePuy Spine] or ProDisc-L® Total Disc
Replacement [Synthes Spine] at 24 months.
Trial Registration: Current Controlled Trials NCT00589797.
Background
Lower back pain is a leading cause of physician patients
report back pain annually in the U.S. Conservative treat-
ment ultimately fails in over 4.5 million patients, and of
these, some 500,000 undergo surgery of the lumbar
spine, of which 200,000 are fusions [1-5].
One of the primary causes of lower back pain is
degeneration of the intervertebral disc. Disc degenera-
tion may result in rupture or herniation, spinal instabil-
ity, articular facet syndrome, or painful impingement on
the nerves enclosed in the spinal visits in the United
States, second only to the common cold. The resultant
pain may also lead to significant disability.
Spinal fusion effectively eliminates the motion seg-
ment between two vertebrae by use of a bone graft,
thereby providing improved stability and decreased pain.
The success rate in spinal fusion has proven highly vari-
able; averaging approximately 60 to 70% [2]. The use of
internal fixation generally increases the fusion rate but
also increases the stiffness of the fused area. This may
lead to increased stress on the adjacent nonfused
segments and, in the case of L5/S1 fusions, on the
sacroiliac joint.
Moreover, in addition to the potential failure to achieve
fusion, the possibility of long-term adverse effects
of fusion has been well documented in the literature.
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pain, pseudoarthrosis, spinal stenosis, spondylolysis
acquisita, and, as a result of the increased stress on the
adjacent spinal segments and the sacroiliac joint, acceler-
ated degenerative changes in the disc and facet joints [1].
Segments adjacent to the spinal fusion may also manifest
disc herniation, degeneration, spinal stenosis, spondyloly-
sis, facet joint arthritis, or instability. The incidence of
the adverse effects reported in the literature is significant,
although highly variable. As many as one third of the
patients who undergo fusion may develop significant
short-term or long-term post-surgical complications [3].
The Activ-L, ProDisc-L and Charité devices are
designed to provide a treatment modality as an alterna-
tive to fusion. These devices are modular systems and
are intended to be used as intervertebral dynamic disc
spacers in the lumbar vertebral region at the L3/L4
(ProDisc-L only), L4/L5 and L5/S1 levels. Disc replace-
ment devices have the advantage of preserving spinal
motion thus potentially avoiding adjacent level disease
and complications secondary to lack of solid fusion.
The ProDisc-L and Charité devices consist of two
endplates composed of a CoCrMo alloy and an ultra
high molecular weight polyethylene (UHMWPE) core.
The endplates are available in a range of endplate and
core sizes and endplate lordosis angles. All ProDisc end-
plates are plasma sprayed with calcium phosphate and
titanium alloy. The Charité device has both coated and
uncoated endplates. The devices are modular so the sur-
geon can select the size and angulation that best fits the
patient’s unique anatomic and physiologic requirements.
The Charité CoCrMo endplates each have six fixation
“teeth” on each side of the endplate for attachment to
the adjacent vertebral bodies while the ProDisc-L has a
central keel and two lateral spikes [6].
The Charité UHMWPE core is a convex bearing sur-
face that fits into a circular groove in the endplate. The
mobile design provides a floating center of rotation. The
ProDisc design incorporates a semi-constrained ball and
socket joint. These devices are designed so that the end-
plates are inserted and secured without the core. After
endplate placement, the disc space is distracted to allow
the core to be seated in the inferior endplate. By com-
parison, the Activ-L is inserted as a single unit and
therefore does not require this second distraction step.
This difference in insertion method is intended to
reduce the risk of over-distraction.
Methods/Design
The following study was reviewed and approved by the
Yale University Human Investigation Committee.
The study proposed is a prospective, randomized, sin-
gle-masked, controlled, multi-center clinical trial con-
sisting of an estimated 414 subjects with single-level
DDD of the lumbar spine (L4/L5, or L5/S1) who have
failed to improve with conservative treatment for at
least six months prior to enrollment. After enrollment,
subjects will be randomized in a 2:1 ratio to either the
Activ-L Disc (investigational device) or the control
(Charité or ProDisc-L). Each investigational site will
have a separate, blocked randomization schedule. Fifteen
(15) to 20 investigational sites will participate in the
investigation. Sites will be encouraged to randomize a
minimum of 10 subjects per site and to implant a mini-
mum of four control devices and sites are bound by a
maximum of 64 subjects. The first three subjects at
each investigational site will receive the Activ-L Disc
and will be not be randomized, these patients will be
outside of the trial. The purpose of these procedures
will be for Surgeon training. Investigators who have
already undergone training in implantation of the con-
trol disc will be selected for participation; however, for
any participating investigator who has not performed at
least three prior control implantations, up to three non-
randomized control implantations may also be per-
formed prior to enrolling randomized subjects into the
study. This will ensure that experience and proficiency
with the implantation method for both discs is compar-
able. Thus, the maximum total enrollment in the study,
including both randomized and nonrandomized cases, is
414 consisting of 261 Activ-L (216 randomized and 45
nonrandomized) and 153 controls (108 randomized and
45 nonrandomized controls). Please refer to figure 1.
The hypothesis of the study is that the Activ-L Disc is
non-inferior to the control (ProDisc-L or Charité) with
respect to the rate of individual subject success at 24
months. Individual subject success is a composite of
effectiveness and safety.
The null hypothesis for the investigation is that the
success rate in the Activ-L group is more than 15%
lower than the success rate in the control group. The
alternative hypothesis is that the success rate in the
Activ-L group is no more than 15% lower than the suc-
cess rate in the control group. The hypotheses will be
evaluated according to the method of Blackwelder [7].
Inclusion Criteria
￿ Age 18 - 60 years and skeletally mature
￿ Symptomatic degenerative disc disease with objec-
tive evidence of lumbar DDD, based on identifica-
tion of any of the following characteristics by MRI
scan:
◦ instability as defined by ≥ 3m mt r a n s l a t i o no r
≥ 5° angulation.
◦ osteophyte formation of facet joints or vertebral
endplates.
◦ decreased disc height of > 2 mm as compared
to the adjacent level.
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annulus fibrosis, or facet joint capsule.
◦ herniated nucleus pulposus.
◦ facet joint degeneration/changes.
◦ vacuum phenomenon.
￿ Single level symptomatic disease at L4/L5 or L5/
S1.
￿ Minimum of six months of unsuccessful conserva-
tive treatment, including but not limited to physical
therapy and/or medication.
￿ Minimum Oswestry Disability Index score of 40/
100.
￿ Subject is a surgical candidate for an anterior
approach to the lumbar spine.
￿ Back pain at the operative level only, with or with-
out leg pain.
￿ Back pain, as measured using a visual analog scale
(VAS), greater than the higher of the two VAS leg
pain scores.
￿ Minimum VAS back pain score of 40/100 mm.
￿ Subject willing and able to return for follow-up
visits regularly and sign an Informed Consent and
HIPAA Authorization.
Exclusion Criteria
￿ Previous surgery at any lumbar level, except IDET
(Intradiscal Electrothermal Annuloplasty), percuta-
neous nucleoplasty, microdiscectomy, hemilaminect-
omy, or laminotomy
￿ Chronic radiculopathy as defined by subject com-
plaint of unremitting pain with a predominance of
Figure 1 Patient progression through both arms of trial.
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extending over a period of at least 1 year.
￿ Anatomic requirements incompatible with the
available range of dimensions for the experimental
or control devices, based on preoperative assessment
using radiographic templates. Specifically, endplate
dimensions smaller than 34.5 mm in medial-lateral
and/or 27 mm in the anterior-posterior direction
￿ Subjects with evidence of significant, symptomatic
disc degeneration at another lumbar level.
￿ Preoperative remaining disc height < 3 mm
￿ Myelopathy.
￿ Previous compression or burst fracture at the
affected level.
￿ Sequestered herniated nucleus pulposus with
migration.
￿ Mid-sagittal stenosis of < 8 mm (by MRI).
￿ Degenerative or lytic spondylolisthesis > 3 mm.
￿ Spondylolysis.
￿ Isthmic spondylolisthesis.
￿ Lumbar scoliosis (> 11° sagittal plane deformity).
￿ Spinal tumor.
￿ Active systemic infection or infection at the site of
surgery.
￿ Facet ankylosis or severe facet degeneration.
￿ Continuing steroid use or prior use for more than
2 months.
￿ History of allergies to any of the device compo-
nents including cobalt chromium alloy, titanium,
ultra high molecular weight polyethylene, and cal-
cium phosphate.
￿ Pregnancy or planning to become pregnant within
the next 2 years.
￿ Morbid obesity (BMI > 35).
￿ Investigational drug or device use within 30 days.
￿ Osteoporosis or osteopenia, indicated by a lumbar
spine DXA T-score less than or equal to -1.
￿ Metabolic bone disease.
￿ Leg pain with migrated sequestrum fragment.
￿ History of rheumatoid arthritis, lupus, or other
autoimmune disorder.
￿ Ankylosing spondylitis.
￿ History of HIV/AIDS or hepatitis that precludes
surgery.
￿ History of deep vein thrombosis, symptoms of
arterial insufficiency, or thromboembolytic disease.
￿ Current or recent history of illicit drug or alcohol
abuse, or dependence as defined as the continued
use of alcohol despite the development of social,
legal, or health problems.
￿ Life expectancy less than 5 years.
￿ Undergone chemotherapy within the past 5 years,
or had any cancer other than non-melanoma skin
cancer treated with curative intent within the past 5
years.
￿ Prior nephrectomy.
￿ Abdominal adhesions, endometriosis, inflammatory
bowel disease, Crohn’s disease, diverticulitis, ulcera-
tive colitis or other abdominal pathology that would
preclude the abdominal surgical approach.
￿ Insulin-dependent diabetes.
￿ Any degenerative muscular or neurological condi-
tion that would interfere with evaluation of out-
comes, including but not limited to Parkinson’s
disease, ALS (amyotrophic lateral sclerosis), or mul-
tiple sclerosis.
￿ History of Pelvic Inflammatory Disease.
￿ Peritonitis.
￿ Subjects currently in active spinal litigation as a
result of medical negligence.
￿ Subject is a prisoner.
￿ Psychiatric or cognitive impairment that, in the
opinion of the investigator, would interfere with the
subject’s ability to comply with the study require-
ments, e.g., Alzheimer’s disease.
Treatment Procedures and Evaluations
Activ-L Disc
All subjects randomized to receive the Activ-L device
will first undergo discectomy to remove the damaged
d i s c ,t h e n( i nt h es a m ep r o cedure) will be implanted
with the device. The Activ-L disc is inserted completely
assembled (endplates and inlay together) and implanted.
No other implanted instrumentation is required to
secure the device position.
Control Discs (ProDisc®-L Total Disc Replacement or
Charité® Artificial Disc)
All subjects randomized to receive one of the control
devices (ProDisc-L or Charité) will first undergo discect-
omy to remove the damaged disc, then (in the same
procedure) will be implanted with the device. Both the
ProDisc-L and Charité implantations are achieved in
two steps. The endplates are first positioned and
inserted, followed by a second distraction step to permit
insertion of the convex UHMWPE core or inlay
between the endplates. No other implanted instrumenta-
tion is required to secure the device position. Please
refer to table 1 for time and event schedules.
Surgical Technique
A standard anterior retroperitoneal approach to the
lower lumbar spine is utilized. A vascular access surgeon
will be used in all cases. The implant comes in two ver-
sions: a keel and a spiked variant. The keel version is
used in cases of extreme concavity of the endplate. In
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is indicated.
After the appropriate level is identified under image
intensification, the midline of the vertebral body is deter-
mined. The spinous process and pedicles serve as rota-
tional aids in determining the midline. Using a curette,
the endplates are cleared of disc residue. A distractor is
then used to mobilize the disc compartment. Under AP
and lateral x-ray views, the trial plates are then inserted.
Care is used to avoid placing the plates too deeply. The
disc space is distracted to a point where the implant will
be held firmly in place, the height measurement is then
read off the distractor. The implant is then assembled on
the back table and attached to the inserter. During
implantation it is imperative that the implant does not
deviate from a central position. The inserter is discon-
nected from the implant and the position of the implant
is checked using image intensification.
Both treatment and control devices will be implanted
anteriorly to ensure comparability between treatment
groups. Blood loss is minimal, averaging approximately
50 cc.
Intraoperative Data Collection
AP and lateral X-rays will be taken intra-operatively and
post-operatively to verify prosthesis placement. Surgical
data collected will include the date and duration of the
surgery, level implanted, blood loss and prosthesis
description. Surgical duration will be measured from the
time of incision to the time of skin closure, skin-to-skin.
All adverse events will be reported. Information will be
collected during the surgical procedure and/or from the
surgical record and will be documented on the Intra-
operative Evaluation Form. The following information
will be collected:
￿ Procedure date, time
￿ Prophylactic antibiotics
￿ Implanted device model number and lot number
￿ Surgery information including duration, approach,
and use of an access surgeon
￿ Vertebral level treated
￿ AP and lateral X-rays to verify device placement
￿ Estimated blood loss
￿ Blood transfusion information (as needed)
Table 1 Time and Events Schedule
Base-
line
Intra-OP Discharge Follow-up Period from Surgery Date (± Days)
6 wks
(± 14)
3 mon
(± 14)
6 mon
(± 30)
12 mon
(± 60)
24 mon
(± 60)
3-5 yrs
(± 60)
Inclusion/Exclusion Determination X
Osteoporosis/
osteopenia screen
X
Medical History/Physical Exam X
Work Status XX X X X X X
Pain Medications XX X X
Antibiotics X X** X
Visual Analog Scale (VAS) Pain Assessment XX X X X X X
Neurological Assessment XX X X X X X X
DVT Prophylaxis X
QOL SF-36 XX X X X X X
Oswestry Disability Index (ODI) XX X X X X X
Hospital Stay X
Range of Motion XX X X X
Subject Satisfaction XXX
Adverse Events XX X X X X X X
RADIOGRAPHIC EVENTS
MRI scan X
DXA Scan X (IR)
X-rays, A/P – Standing Neutral XX
(Implant Position)
X
(Implant Position)
XXX X X X
X-rays, A/P- Right/Left Bending XX X X X X X
X-rays, Lateral - Flexion-Extension XX X X X X X
X-Rays, Lateral Standing
Neutral
XX
(Implant Position)
X
(Implant Position)
XXX X X X
IR: If required
** Prophylactic antibiotics
Yue and Mo BMC Surgery 2010, 10:14
http://www.biomedcentral.com/1471-2482/10/14
Page 5 of 8￿ Adverse Events
￿ Any implant sizing difficulties
Primary Endpoints
Individual subject success will be defined as:
￿ Improvement of at least 15 points in the Oswestry
Disability Index score at 24 months compared to
baseline.
￿ Maintenance or improvement in neurological sta-
tus at 24 months compared to baseline as measured
by motor and sensory evaluations. A decrease of one
grade in either evaluation will be considered a
failure.
￿ Maintenance or improvement in motion at the
index level, defined as:
24 month ROM - preoperative ROM ≥ 0( w i t h±2 °
measurement error applied) in a patient who does
not meet the definition of fusion.
Fusion as defined in the radiographic protocol will
be considered a failure.
￿ No device failures requiring revision, re-operation,
removal, or supplemental fixation.
￿ Absence of serious device-related adverse events
(AEs). For purposes of this study, serious device-
related adverse events are defined as serious device-
related adverse events as adjudicated by the Clinical
Events Committee.
For purposes of evaluating the primary endpoint, the
Clinical Events Committee will determine if an adverse
event is device-related. However, the investigator’s
assessment will also be reported.
For purposes of the above endpoint definition, the
terms “revision,”“ re-operation,”“ removal,” and “supple-
mental fixation” are defined as follows:
￿ A revision is a procedure that adjusts or in any
way modifies or removes part of the original implant
configuration, with or without replacement of a
component. A revision may also include adjusting
the position of the original configuration.
￿ A removal is a procedure where the entire original
system configuration is removed with or without
replacement.
￿ A re-operation is any surgical procedure at the
involved level(s) that does not include removal,
modification, or addition of any components to the
system.
￿ A supplemental fixation is a spinal procedure in
which additional instrumentation not under study in
the protocol is implanted (e.g., supplemental place-
ment of a rod/screw system or a plate/screw system).
In addition, any subsequent procedures related to
the index level should be reported. This would
include posterior fusion, leaving or removing a
motion retaining device in place, decompression,
facet rhizotomy, etc at the same, adjacent or distant
levels.
Powered Secondary Endpoints
￿ Back Pain, measured at rest using a visual analog
scale (VAS); improvement of 20 mm or more on a
100 mm VAS scale at 24 months compared to base-
line will be considered clinically significant.
￿ Leg Pain, measured at rest using a visual analog
scale (VAS). The success rate will be formally tested
for superiority in the Activ-L group. A patient will
be considered a responder if, at the 24 month visit
they achieve at least a 20 mm VAS improvement in
the leg with the maximum pain at baseline, with no
worsening in the other leg.
Unpowered Secondary Endpoints
￿ The mean Oswestry Disability Index score, as well
as the mean improvement, will be compared
between groups across all study visits. The incidence
of both 15% and 15 point improvements will also be
compared.
￿ Quality of Life, measured using the Short Form-36
Questionnaire (SF-36); improvement of 15% in the
overall score at 24 months compared to baseline will
be considered clinically significant.
￿ Disc height (incidence of 3 mm change), as mea-
sured by standard lateral radiograph. Comparison of
disc height to the 6-week height will also be per-
formed to account for the expected degree of
immediate post-operative “settling” of the prosthesis.
￿ Incidence of subsidence of the device (> 3 mm) at
the 24-month visit.
￿ Neurological status at 24 months compared to
baseline.
￿ The mean operative time.
￿ Safety: The individual incidence rates of all adverse
events through 24 months follow-up.
￿ Each subject will remain in the study for 5 years
post treatment. It is expected to take 6 years to col-
lect all required data for this study.
Power Analysis
Power analysis was performed using the PASS 2005
software. (NCSS Kaysville, Utah)The PASS 2005 output
solves for what the true success rate must be in the
A c t i v - Lg r o u pi no r d e rt oh a v e8 0 %p o w e rt od e t e c t
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in the control group (plausible range 50-80%). All calcu-
lations assume a power of 80% and a two-sided signifi-
cance level of 0.05. Note that for each case, the required
margin of improvement is not particularly onerous. For
example, if the true success rate in the control group is
50%, the true success rate in the treatment group need
only be 68%. If the control rate is 80%, the Activ-L rate
need only be 92%.
Therefore, with the sample size required to demonstrate
the primary composite endpoint, this study is adequately
powered to detect a reasonable, yet clinically meaningful
difference in rates if Activ-L truly produces greater
improvement in pain over time. Please refer to table 2.
Follow Up Evaluations
Subjects will be followed at 6-weeks (± 14 days), 3-
months (± 14 days), 6-months (± 30 days), 12-months
(± 60 days) and 24-months (± 60 days). After comple-
tion of the 24-month follow-up, subjects will continue
to be evaluated annually for 3 additional years (± 60
days) to gather additional long-term information. Infor-
mation will be collected on the Follow-up Visit Form
and the Individual forms for VAS, ODI and SF-36. The
following information will be recorded as shown below.
Data collected at 6 weeks and 3 months will include:
￿ AP/Lateral, flexion/extension, and side bending
standing x-rays
￿ Work status
￿ VAS Pain assessment (back, right and left leg)
￿ Oswestry Disability Index score
￿ Quality of life assessment (SF-36)
￿ Neurological assessment
￿ Adverse events
Data collected at 6 months will include:
￿ AP/Lateral, flexion/extension, and side bending
standing x-rays
￿ Work status
￿ VAS Pain assessment (back, right and left leg)
￿ Oswestry Disability Index score
￿ Quality of life assessment (SF-36)
￿ Neurological assessment
￿ Range of Motion
￿ Adverse events
Data collected at 12 and 24 months will include:
￿ AP and Lateral, flexion/extension and lateral bend-
ing X-rays
￿ Work status
￿ VAS Pain assessment (back, right and left leg)
￿ Oswestry Disability Index score
￿ Quality of life assessment (SF-36)
￿ Neurological assessment
￿ Pain medication status
￿ Range of Motion
￿ Subject satisfaction
￿ Adverse events
The same follow-up information will be collected at
subsequent annual visits through year 5 with the excep-
tion of the MRI scan and pain medication usage.
To collect data concerning the integrity of the blind,
subjects will be asked at each follow-up visit if, since the
prior visit, they have learned which device they received.
Justification for Pooling Data across Centers
The proposed investigation is a multi-center trial in the
US, where all centers will be trained to use the same
study protocol. The appropriateness of pooling data
from multiple centers is necessarily enhanced by train-
ing all participating centers to follow the same protocol,
with clearly defined inclusion and exclusion criteria for
study participation. However, if an interaction is present
between treatment and center effects, the results will
not be strictly poolable. Thus, in order to protect against
improperly pooling data from all study centers, a formal
Table 2 Power Analysis results using PASS 2005 Software (NCSS Kayesville, Utah) PASS 2005 Power Analysis Results.
Sample Size
Group 1
Sample Size
Group 2
Group 1 or
Treatment
Group 2 or
Control
Diff if H0 Diff if H1
Power N1 N2 P1.1 P2 D0 D1 Target Alpha Beta
0.8000 178 89 0.6771 0.5000 0.0000 0.1771 0.0500 0.2000
0.8000 178 89 0.7227 0.5500 0.0000 0.1727 0.0500 0.2000
0.8000 178 89 0.7665 0.6000 0.0000 0.1665 0.0500 0.2000
0.8000 178 89 0.8086 0.6500 0.0000 0.1586 0.0500 0.2000
0.8000 178 89 0.8487 0.7000 0.0000 0.1487 0.0500 0.2000
0.8000 178 89 0.8865 0.7500 0.0000 0.1365 0.0500 0.2000
0.8000 178 89 0.9218 0.8000 0.0000 0.1218 0.0500 0.2000
Two Independent Proportions (Null Case) Power Analysis Numeric Results of Tests Based on the Difference: P1 - P2 H0: P1-P2 = 0. H1: P1-P2 = D1 <> 0. Test
Statistic: Z test with pooled variance
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of pooling the data [8].
For the primary endpoint, a logistic regression will be
constructed that models the success rate on three factors:
treatment group, center, and the treatment group by cen-
ter interaction. If the interaction term is significant at a
two-sided a = 0.05 level of significance, then the offend-
ing center(s) will be identified and all analyses will be
presented in a stratified fashion, since pooling the results
would make interpretation of the trial difficult.
If, on the other hand, the interaction term is insignifi-
cant but the center term is significant, then fixed effects
for center will be added to the final models for, at a
minimum, the primary endpoint. Controlling for con-
founding center effects in this fashion is a well-accepted
technique.
Discussion
Present treatment for disc degeneration ranges from
conservative modalities, such as rest, heat, electrother-
apy, physical therapy, and analgesics to surgery. Cur-
rently, there are two main surgical techniques for
treatment of disc degeneration: (1) nucleotomy or dis-
cectomy, i.e., excision of part or all of the degenerated
disc, which is typically performed for treatment of radi-
cular syndrome in the case of disc herniation; and (2)
spinal fusion, i.e. grafting bone between the vertebrae
adjacent to the degenerated disc to eliminate articula-
tion at the damaged reduction of the intervertebral
space. Rigid internal fixation may also be used to pro-
mote fusion.
The Activ-L Disc is designed to provide a new thera-
peutic option for treatment of degenerative disc disease
as an alternative to spinal fusion to preserve function in
the lumbar vertebral region. By allowing motion at the
diseased segment the replacement disc would limit the
advance of adjacent level disease as well as preclude the
need for fusion.
The Activ-L, ProDisc-L and Charité devices are
designed to provide a treatment modality as an alterna-
tive to fusion [9]. These devices are modular systems
and are intended to be used as intervertebral dynamic
disc spacers in the lumbar vertebral region at the L3/L4
(ProDisc-L only), L4/L5 and L5/S1 levels.
Our study will further allow the generation of results
comparing fusions with the two types of disc replace-
ments in treating degeneration in the lumbar spine. The
results will have a relevant impact on providing addi-
tional safety and efficacy data in regards to a promising
alternative to lumbar spine fusions.
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